论文部分内容阅读
一项荟萃分析提示使用血管紧张素Ⅱ受体拮抗药(ARBs)与新发癌症风险轻度增加相关。新近FDA公布的审查结果和新发表的研究(2项荟萃分析、2项观察性队列研究和1项注册研究)并未证实两者之间具有相关性,FDA结论为使用ARBs不增加新发肿瘤的风险。使用ARBs的益处超过其风险,有适应证可继续使用。本文主要对ARBs与发生肿瘤风险之间的关系、可能机制和临床证据加以讨论。
A meta-analysis suggests that the use of angiotensin II receptor antagonists (ARBs) is associated with a modest increase in the risk of new cancers. Recent findings of the FDA review and newly published studies (2 meta-analyzes, 2 observational cohort studies and 1 registry study) did not confirm the correlation between the two, and the FDA concluded that the use of ARBs did not increase the incidence of new tumors risks of. The benefits of using ARBs outweigh the risks and the indications continue to be used. This article focuses on the relationship between ARBs and the risk of developing the tumor, possible mechanisms and clinical evidence to be discussed.